<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107494</url>
  </required_header>
  <id_info>
    <org_study_id>CS002</org_study_id>
    <nct_id>NCT03107494</nct_id>
  </id_info>
  <brief_title>Gala FIH Feasibility Study for the Treatment of Chronic Bronchitis</brief_title>
  <official_title>A Feasibility Study: A Safety Evaluation of the Gala Airway Treatment System on Patients With Chronic Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gala Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gala Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility trial (FIH) to assess the safety and clinical utility in patients with chronic
      bronchitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Gala Airway Treatment system is a device-based, energy delivery system that delivers high
      frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The
      energy is delivered via a proprietary catheter through the bronchoscope.

      Two sessions of treatment will be delivered one month apart. The right lung is treated at the
      first treatment session and the left lung is treated at the second treatment session
      (approximately one month after the right side is treated). Treatment will be delivered by a
      respiratory physician (interventional pulmonologist) in a tertiary teaching hospital during a
      bronchoscopic procedure. The bronchoscopy will be delivered during general anaesthesia. It is
      anticipated that the bronchoscopic procedure will last less than 60 minutes in total.
      Treatment will be deemed to have been delivered following the successful treatment during the
      two bronchoscopies.

      A third bronchoscopy will be performed three months following the second treatment session
      where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that
      have been treated during the two previous bronchoscopic treatment session to evaluate the
      effect of the treatment on the airways producing excessive mucous.

      Subjects will be required to submit to several tests during the study including two CT scans
      (lung), respiratory function tests, exercise testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Treatment with Gala Airway Treatment System</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and evaluation of any serious adverse events associated with the Gala Airway Treatment System through 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence and evaluation of any serious adverse events associated with the Gala Airway Treatment System through 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Utility - Histology</measure>
    <time_frame>12 months following treatment session number 2</time_frame>
    <description>Histopathological evidence of change in mucus producing cells within the airway.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Utility - Pulmonary Function</measure>
    <time_frame>Pulmonary function testing measured at 1week, 3 months, 6 months and 12 months post treatment number 2</time_frame>
    <description>Pulmonary function testing utilizing the FEV1 and FVC tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Quality of Life Indices will be completed at 1 week post treatment 1, at treatment 2, and 1 week, 3 months, 6 months and 12 months post treatment 2</time_frame>
    <description>Patient filled respiratory questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Exacerbations</measure>
    <time_frame>Between 48 hours post procedure (1st or 2nd treatment procedures and 3rd biopsy procedure) and the end of the patient's participation in the study (up to 1 year following final treatment session)</time_frame>
    <description>Detection of acute exacerbations (measured by clinical examination of a suitably qualified physician)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>Treatment with GATS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gala Airway Treatment System (GATS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gala Airway Treatment System</intervention_name>
    <description>The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.</description>
    <arm_group_label>Treatment with GATS</arm_group_label>
    <other_name>GATS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is diagnosed with chronic bronchitis for a minimum of two years, where chronic
             bronchitis is defined clinically as chronic productive cough for three months in each
             of two successive years in a patient in whom other causes of productive cough have
             been excluded.

          2. Subject has GOLD Stage II chronic obstructive pulmonary disease (COPD) with a
             preprocedure post-bronchodilator FEV1 of greater than or equal to 50% and less than or
             equal to 80% of predicted within three months of enrollment.

          3. Subject has been treated with Long Acting Beta Agonists (LABAs) or Long Acting
             Muscarinic Antagonists (LAMAs) or both for three months or more.

          4. Subject has a cigarette smoking history of at least ten packs years.

          5. Subject in the opinion of the site investigator can undertake the processes and
             procedures of the clinical trial and has provided a signed informed consent.

        Exclusion Criteria:

          1. Subject has active respiratory infection (e.g., common cold, pneumonia, MAI,
             tuberculosis) or COPD exacerbation within the last three months.

          2. Subject has MMRC score greater than or equal to 3.

          3. Subject is treated with inhaled corticosteroids (ICS) within the last 4 weeks.

          4. Subject has an implantable cardioverter defibrillator or pacemaker.

          5. Subject has a history of cardiac arrhythmia within past two years.

          6. Subject has abnormal cardiac rhythm at time of procedure.

          7. Subject has history of proven lung cancer in last 5 years.

          8. Subject has pulmonary nodule or cavity requiring follow-up or intervention unless
             proven benign and not actively infected (e.g., aspergilloma).

          9. Subject has prior lung surgery, such as lung transplant, LVRS, lung
             implant/prosthesis, metal stent, valves, coils, bullectomy, segmentectomy, or
             lobectomy. Pneumothorax without lung resection is acceptable. Pleural procedures
             without surgery are acceptable.

         10. Subject has Alpha-1-Antitrypsin (AAT) deficiency.

         11. Subject has documented history of asthma diagnosed with onset &lt;30 years of age,
             clinically significant bronchiectasis or any other significant second lung disease.

         12. Subject actively smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.)
             within the last 6 months.

         13. Subject has known airway colonization with resistant organisms including but not
             limited to pseudomonas, MRSA, B Cepacia, MTB, M abscessus, mucor or any significant
             fungus.

         14. Subject has the inability to walk over 140 meters.

         15. Subject has a serious medical condition, such as: uncontrolled congestive heart
             failure, uncontrolled angina, myocardial infarction in the past year, renal failure,
             liver disease, cerebrovascular accident within the past 6 months, uncontrolled
             diabetes, hypertension, autoimmune disease or uncontrolled gastric reflux.

         16. Subject has known sensitivity to medication required to perform bronchoscopy (such as
             lidocaine, atropine, and benzodiazepines).

         17. Subject is pregnant, nursing, or planning to get pregnant during study duration.

         18. Subject has received chemotherapy within the past 6 months or is expected to receive
             chemotherapy during participation in this study.

         19. Subject is or has been in another clinical investigational study within 6 weeks of
             baseline.

         20. Subject on anticoagulation for cardiovascular indications and is unable to have
             anticoagulants (i.e., Aspirin, Plavix, Coumadin) withheld for at least seven days
             prior to bronchoscopy in the opinion of the Investigator.

        18. Subject is or has been in another clinical investigational study within 6 weeks of
        baseline.

        19.Subject on anticoagulation for cardiovascular indications is unable to have
        anticoagulants (i.e., Aspirin, Plavix, Coumadin) withheld for at least seven days prior to
        bronchoscopy in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Waldstreicher, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gala Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Waldstreicher, MD</last_name>
    <email>jon@galatherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah Sheffield, MS</last_name>
    <email>deb@galatherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Otto Wagner Spital</name>
      <address>
        <city>Wien</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arschang Valipour, MD</last_name>
      <phone>0043 664 4385355</phone>
      <email>blvr.koordinator@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Arschang Valiour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Alemana</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Bascu√±an</last_name>
      <phone>569 934 65819</phone>
      <email>cbascunan@alemana.cl</email>
    </contact>
    <investigator>
      <last_name>Sebastian Fernandez-Bussy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Chile</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

